

# Lisinopril

sc-205732

## Material Safety Data Sheet



The Power to Question

Hazard Alert Code  
Key:

EXTREME

HIGH

MODERATE

LOW

## Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION


### PRODUCT NAME

Lisinopril

### STATEMENT OF HAZARDOUS NATURE

CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200.

### NFPA



### SUPPLIER

Company: Santa Cruz Biotechnology, Inc.

Address:

2145 Delaware Ave

Santa Cruz, CA 95060

Telephone: 800.457.3801 or 831.457.3800

Emergency Tel: CHEMWATCH: From within the US and  
Canada: 877-715-9305

Emergency Tel: From outside the US and Canada: +800 2436  
2255 (1-800-CHEMCALL) or call +613 9573 3112

### PRODUCT USE

Antihypertensive. Inhibitor of the enzyme involved in the conversion of angiotensin I to angiotensin II. Also used in the treatment of congestive heart failure. Normally given by mouth. A lysine analogue of enalapril. Lisinopril appears to be less effective in blacks than in caucasians.

### SYNONYMS

C21-H31-N3-O5.2H2O, "L-proline, 1-[N(sup 2)-(1-carboxy-3-phenylpropyl)-L-lysyl]-, dihydrate, ", "L-proline, 1-[N(sup 2)-(1-carboxy-3-phenylpropyl)-L-lysyl]-, dihydrate, ", (S)-, "(S)-1-[N(sup 2)-1-(carboxy-3-phenylpropyl)-L-lysyl]-L-proline", dihydrate, "(S)-1-[N(sup 2)-1-(carboxy-3-phenylpropyl)-L-lysyl]-L-proline", dihydrate, Lisinopril, Lisodur, "MK 0521", "MK 521", "MK 522", MK-521, Prinivil, Prinvil, Zestril, Carace, "angiotensin converting enzyme (ACE) inhibitor", antihypertensive

## Section 2 - HAZARDS IDENTIFICATION

### CANADIAN WHMIS SYMBOLS



### EMERGENCY OVERVIEW RISK

### POTENTIAL HEALTH EFFECTS

### ACUTE HEALTH EFFECTS

### SWALLOWED

- Accidental ingestion of the material may be damaging to the health of the individual.

■ ACE inhibitors are fairly safe and serious overdoses are rare. Overdoses may cause low blood pressure, increased heart rate and reversible kidney failure. Side effects of treatment include itch, rash, taste disturbance, allergy, loss of white blood cells, stomach upset, low blood pressure, increased heart rate, mouth ulcers, "pins and needles" in the hands, cough, wheeze and swollen lymph nodes. Damage to the kidneys and low blood pressure may be severe. Large areas of swelling may occur in the tongue, lips, face, extremities, and throat, which may be life-threatening. An itchy skin rash with redness and blistering may occur. Symptoms of low blood pressure are more likely in people who have been on low salt diets and prolonged treatment with diuretics. ACE inhibitors can cause reduction in urine output, and rarely, death due to kidney failure.

#### EYE

■ Although the material is not thought to be an irritant, direct contact with the eye may cause transient discomfort characterized by tearing or conjunctival redness (as with windburn). Slight abrasive damage may also result. The material may produce foreign body irritation in certain individuals.

#### SKIN

■ The material is not thought to produce adverse health effects or skin irritation following contact (as classified using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an occupational setting.

■ Open cuts, abraded or irritated skin should not be exposed to this material.

■ Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.

#### INHALED

■ The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified using animal models). Nevertheless, adverse effects have been produced following exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.

■ Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.

#### CHRONIC HEALTH EFFECTS

■ Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.

Based on experience with animal studies, there is a possibility that exposure to the material may result in toxic effects to the development of the fetus, at levels which do not cause significant toxic effects to the mother.

Long term exposure to high dust concentrations may cause changes in lung function i.e. pneumoconiosis; caused by particles less than 0.5 micron penetrating and remaining in the lung. Prime symptom is breathlessness; lung shadows show on X-ray.

ACE inhibitors may aggravate kidney and collagen vascular disorders. They may cause injury and death to the fetus late in pregnancy. There has been low blood pressure of the newborn, kidney failure, underdevelopment of the skull and lungs, insufficient amniotic fluid, and fetal growth retardation and limb contractures. Miscarriage or stillbirth may occur. ACE inhibitors can cause growths in glands, but rarely cause malignant cancer.

Exposure to small quantities may induce hypersensitivity reactions characterized by acute bronchospasm, hives (urticaria), deep dermal wheals (angioneurotic edema), running nose (rhinitis) and blurred vision. Anaphylactic shock and skin rash (non-thrombocytopenic purpura) may occur. An individual may be predisposed to such anti-body mediated reaction if other chemical agents have caused prior sensitization (cross-sensitivity).

Kidney and liver effects were observed in repeat-dose oral toxicity studies with enalapril, up to 1-year in duration, in dogs. The no-observed-adverse-effect level (NOEL) was 15 mg/kg/day.






No teratogenic effects of oral lisinopril were seen in studies of pregnant rats and rabbits.

There was no evidence of a tumourigenic effect when enalapril was administered for 106 weeks at doses up to 90 mg/kg/day (150 times the maximum daily human dose). Enalapril has also been administered for 94 weeks to male and female mice at doses up to 90 and 180 mg/kg/day, respectively (150 and 300 times the maximum daily human dose) and shows no evidence of carcinogenicity. Neither enalapril maleate or its active diacid are mutagenic in the Ames microbial mutagen test with or without metabolic activation.

Lisinopril is negative in a battery of mutagenic tests.

## Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS

### HAZARD RATINGS

		Min	Max
Flammability:	1		
Toxicity:	2		
Body Contact:	0		
Reactivity:	1		
Chronic:	2		

Min/Nil=0  
Low=1  
Moderate=2  
High=3  
Extreme=4

NAME	CAS RN	%
lisinopril	83915-83-7	>98

## Section 4 - FIRST AID MEASURES

### SWALLOWED

- 
- If swallowed do NOT induce vomiting.
- If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration.
- Observe the patient carefully.
- Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious.
- Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink.
- Seek medical advice.

## EYE

■ If this product comes in contact with the eyes:

- Wash out immediately with fresh running water.
- Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.
- If pain persists or recurs seek medical attention.
- Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.

## SKIN

■ If skin or hair contact occurs:

- Flush skin and hair with running water (and soap if available).
- Seek medical attention in event of irritation.

## INHALED

■

- If dust is inhaled, remove from contaminated area.
- Encourage patient to blow nose to ensure clear passage of breathing.
- If irritation or discomfort persists seek medical attention.

## NOTES TO PHYSICIAN

■ Supportive care should be given in overdose. The patient should be given adequate fluids, if necessary with IV fluids, to maintain a satisfactory blood pressure and a good urine output. If patients are well after 6 hours, they are considered medically fit for discharge. Oral activated charcoal may be given to patients who have ingested a large overdose if they present within a few hours. There is unlikely to be a significant benefit from repeated doses of activated charcoal. Hemodialysis may increase the clearance of some drug but there is no indication for the procedure. While angiotensin II is a logical antidote for overdose, it is not generally available and should not be required. Hypotension should be treated with IV fluids (normal saline) and positioning of the patient. A central line may be useful to monitor fluid replacement in patients with heart failure or severe renal impairment. Small doses of vaso-constrictors (e.g. adrenalin) may be given if the patient fails to respond. Most ACE inhibitors (except captopril and lisinopril) are given as pro-drugs which have little activity. These pro-drugs have good bioavailability and are generally well absorbed. They are rapidly metabolized by esterases to active metabolites (generally the diacids). Captopril and lisinopril are not as well absorbed and have lower bioavailability than the pro-drugs. Naming convention adds the extension "prilat" to the common name of the pro-drug.

BIOAVAILABILITY:

Drug	Time to Peak (hrs)	Bioavailability %	Urinary excretion of active moiety (normal renal function)	Approx. half-life (hrs)!
Alacepril *				
Altiopril *				
Benazepril*				
Captopril	0.7-1.3	65	>70	3.5-32**
Cilazapril*				
Delapril *		50		1.2-12.9**
Enalapril *		>50		8-36**
Fosinopril*				
Lisinopril			88	6-19.5**
Moexipril				
Pentopril *		60-70		2.7-10.5**
Perindopril*				5.0-31 **
Quinapril *			>50	5.0-31**
Ramipril *			20-40	8.0-16.0**
Spirapril *				
Trandopril*				
Zofenopril*				

\* Given as the pro-drug; activity is due to metabolites (-prilat)

\*\* Higher figure for patients with renal failure

! Most ACE inhibitors have biphasic kinetics; figures are for apparent half-lives

HyperTox 3.0 <http://www.newcastle.edu.au/departments/md/htas/ACE00001.HTML>

When involvement of the tongue, glottis or larynx is likely to cause airway obstruction, appropriate therapy (e.g. adrenalin) should be promptly administered. Medical therapy of progressive edema should be aggressive. Failing a rapid response, mechanical methods to secure an airway should be undertaken before massive edema complicates oral or nasal intubation or surgical procedures. (e.g. cricothyroidotomy or tracheostomy). Patients responding to medical treatment should be observed carefully for a possible rebound phenomenon. Monitoring of white blood cell counts, especially in patients with collagen vascular disease and/or renal disease is advisable during ACE therapy due to the appearance of agranulocytosis and bone-marrow depression in some patients. Australian Prescriptions Product Guide.

Following oral administration, peak serum concentrations of lisinopril occur within about 7 hours. Declining serum concentrations exhibit a prolonged terminal phase which does not contribute to drug accumulation and probably represents saturable binding to ACE; it is not proportional to dose. Lisinopril does not undergo metabolism and is excreted almost entirely unchanged in the urine. On multiple dosing lisinopril exhibits an effective half-life of accumulation of 12 hours.

Lisinopril can be removed by haemodialysis. for enalapril:

Hypotension may be treated by intravenous infusion of normal saline solution.

Merck, Sharp and Dohme.

## Section 5 - FIRE FIGHTING MEASURES

Vapour Pressure (mmHG):	Negligible
Upper Explosive Limit (%):	Not available.
Specific Gravity (water=1):	Not available
Lower Explosive Limit (%):	Not available

## EXTINGUISHING MEDIA

- 
- Foam.
- Dry chemical powder.
- BCF (where regulations permit).
- Carbon dioxide.
- Water spray or fog - Large fires only.

## FIRE FIGHTING

- 
- Alert Emergency Responders and tell them location and nature of hazard.
- Wear breathing apparatus plus protective gloves.
- Prevent, by any means available, spillage from entering drains or water course.
- Use water delivered as a fine spray to control fire and cool adjacent area.
- DO NOT approach containers suspected to be hot.
- Cool fire exposed containers with water spray from a protected location.
- If safe to do so, remove containers from path of fire.
- Equipment should be thoroughly decontaminated after use.

## GENERAL FIRE HAZARDS/HAZARDOUS COMBUSTIBLE PRODUCTS

- 
- Combustible solid which burns but propagates flame with difficulty.
- Avoid generating dust, particularly clouds of dust in a confined or unventilated space as dusts may form an explosive mixture with air, and any source of ignition, i.e. flame or spark, will cause fire or explosion. Dust clouds generated by the fine grinding of the solid are a particular hazard; accumulations of fine dust may burn rapidly and fiercely if ignited.
- Dry dust can be charged electrostatically by turbulence, pneumatic transport, pouring, in exhaust ducts and during transport.
- Build-up of electrostatic charge may be prevented by bonding and grounding.
- Powder handling equipment such as dust collectors, dryers and mills may require additional protection measures such as explosion venting.

Combustion products include: carbon monoxide (CO), carbon dioxide (CO<sub>2</sub>), nitrogen oxides (NO<sub>x</sub>), sulfur oxides (SO<sub>x</sub>), other pyrolysis products typical of burning organic material.

May emit poisonous fumes.

## FIRE INCOMPATIBILITY

- Avoid contamination with oxidizing agents i.e. nitrates, oxidizing acids, chlorine bleaches, pool chlorine etc. as ignition may result.

## PERSONAL PROTECTION

Glasses:

Chemical goggles.

Gloves:

Respirator:

Particulate

## Section 6 - ACCIDENTAL RELEASE MEASURES

### MINOR SPILLS

- 
- Clean up waste regularly and abnormal spills immediately.
- Avoid breathing dust and contact with skin and eyes.
- Wear protective clothing, gloves, safety glasses and dust respirator.
- Use dry clean up procedures and avoid generating dust.
- Vacuum up or sweep up. NOTE: Vacuum cleaner must be fitted with an exhaust micro filter (HEPA type) (consider explosion-proof machines designed to be grounded during storage and use).
- Dampen with water to prevent dusting before sweeping.
- Place in suitable containers for disposal.

### MAJOR SPILLS

- Moderate hazard.
- CAUTION: Advise personnel in area.
- Alert Emergency Responders and tell them location and nature of hazard.
- Control personal contact by wearing protective clothing.
- Prevent, by any means available, spillage from entering drains or water courses.
- Recover product wherever possible.
- IF DRY: Use dry clean up procedures and avoid generating dust. Collect residues and place in sealed plastic bags or other containers for disposal. IF WET: Vacuum/shovel up and place in labelled containers for disposal.
- ALWAYS: Wash area down with large amounts of water and prevent runoff into drains.
- If contamination of drains or waterways occurs, advise emergency services.

## ACUTE EXPOSURE GUIDELINE LEVELS (AEGL) (in ppm)

AEGL 1: The airborne concentration of a substance above which it is predicted that the general population, including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic nonsensory effects. However, the effects are not disabling and are transient and reversible upon cessation of exposure.

AEGL 2: The airborne concentration of a substance above which it is predicted that the general population, including susceptible individuals, could experience irreversible or other serious, long-lasting adverse health effects or an impaired ability to escape.

AEGL 3: The airborne concentration of a substance above which it is predicted that the general population, including susceptible individuals, could experience life-threatening health effects or death.

## Section 7 - HANDLING AND STORAGE

### PROCEDURE FOR HANDLING



- Avoid all personal contact, including inhalation.
- Wear protective clothing when risk of exposure occurs.
- Use in a well-ventilated area.
- Prevent concentration in hollows and sumps.
- DO NOT enter confined spaces until atmosphere has been checked.
- DO NOT allow material to contact humans, exposed food or food utensils.
- Avoid contact with incompatible materials.
- When handling, DO NOT eat, drink or smoke.
- Keep containers securely sealed when not in use.
- Avoid physical damage to containers.
- Always wash hands with soap and water after handling.
- Work clothes should be laundered separately.
- Launder contaminated clothing before re-use.
- Use good occupational work practice.
- Observe manufacturer's storing and handling recommendations.
- Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.

Empty containers may contain residual dust which has the potential to accumulate following settling. Such dusts may explode in the presence of an appropriate ignition source.

- Do NOT cut, drill, grind or weld such containers
- In addition ensure such activity is not performed near full, partially empty or empty containers without appropriate workplace safety authorisation or permit.

### RECOMMENDED STORAGE METHODS



- Glass container.
- Polyethylene or polypropylene container.
- Check all containers are clearly labelled and free from leaks.

### STORAGE REQUIREMENTS



- Store in original containers.
- Keep containers securely sealed.
- Store in a cool, dry, well-ventilated area.
- Store away from incompatible materials and foodstuff containers.
- Protect containers against physical damage and check regularly for leaks.
- Observe manufacturer's storing and handling recommendations.

### SAFE STORAGE WITH OTHER CLASSIFIED CHEMICALS



X: Must not be stored together

O: May be stored together with specific preventions

+: May be stored together

## Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION

### EXPOSURE CONTROLS

The following materials had no OELs on our records

- lisinopril: CAS:83915-83-7 CAS:76547-98-3

### MATERIAL DATA

#### LISINOPRIL:

■ Airborne particulate or vapor must be kept to levels as low as is practicably achievable given access to modern engineering controls and monitoring hardware. Biologically active compounds may produce idiosyncratic effects which are entirely unpredictable on the basis of literature searches and prior clinical experience (both recent and past).

CEL TWA: 0.1 mg/m<sup>3</sup> (Merck, Sharp and Dohme)

In normotensive patients, 1 mg is ineffective in reducing blood pressure and is considered to be the no-effect-level. In order that 1 mg is not exceeded in an 8-hour day, a exposure limit of 0.1 mg/m<sup>3</sup> is recommended.

## PERSONAL PROTECTION



Consult your EHS staff for recommendations

### EYE

■ When handling very small quantities of the material eye protection may not be required.

For laboratory, larger scale or bulk handling or where regular exposure in an occupational setting occurs:

- Chemical goggles
- Face shield. Full face shield may be required for supplementary but never for primary protection of eyes
- Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lens or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59]

### HANDS/FEET

■ Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include: such as:

- frequency and duration of contact,
- chemical resistance of glove material,
- glove thickness and
- dexterity

Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739).

- When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374) is recommended.
- When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374) is recommended.
- Contaminated gloves should be replaced.

Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.

- Rubber gloves (nitrile or low-protein, powder-free latex). Employees allergic to latex gloves should use nitrile gloves in preference.
- Double gloving should be considered.
- PVC gloves.
- Protective shoe covers.
- Head covering.

Experience indicates that the following polymers are suitable as glove materials for protection against undissolved, dry solids, where abrasive particles are not present.

- polychloroprene
- nitrile rubber
- butyl rubber
- fluorocautchouc
- polyvinyl chloride

Gloves should be examined for wear and/ or degradation constantly.

### OTHER

- 
- For quantities up to 500 grams a laboratory coat may be suitable.
- For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar and cuffs.
- For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers.
- For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection.
- Eye wash unit.
- Ensure there is ready access to an emergency shower.
- For Emergencies: Vinyl suit

- 
- Respirators may be necessary when engineering and administrative controls do not adequately prevent exposures.
- The decision to use respiratory protection should be based on professional judgment that takes into account toxicity information, exposure measurement data, and frequency and likelihood of the worker's exposure - ensure users are not subject to high thermal loads which may result in heat stress or distress due to personal protective equipment (powered, positive flow, full face apparatus may be an option).
- Published occupational exposure limits, where they exist, will assist in determining the adequacy of the selected respiratory. These may be government mandated or vendor recommended.
- Certified respirators will be useful for protecting workers from inhalation of particulates when properly selected and fit tested as part of a complete respiratory protection program.
- Use approved positive flow mask if significant quantities of dust becomes airborne.
- Try to avoid creating dust conditions.

### RESPIRATOR

Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
10 x PEL	P1	-	PAPR-P1



	Air-line*	-	-
50 x PEL	Air-line**	P2	PAPR-P2
100 x PEL	-	P3	-
		Air-line*	-
100+ x PEL	-	Air-line**	PAPR-P3

\* - Negative pressure demand \*\* - Continuous flow

Explanation of Respirator Codes:

Class 1 low to medium absorption capacity filters.

Class 2 medium absorption capacity filters.

Class 3 high absorption capacity filters.

PAPR Powered Air Purifying Respirator (positive pressure) cartridge.

Type A for use against certain organic gases and vapors.

Type AX for use against low boiling point organic compounds (less than 65°C).

Type B for use against certain inorganic gases and other acid gases and vapors.

Type E for use against sulfur dioxide and other acid gases and vapors.

Type K for use against ammonia and organic ammonia derivatives

Class P1 intended for use against mechanically generated particulates of sizes most commonly encountered in industry, e.g. asbestos, silica.

Class P2 intended for use against both mechanically and thermally generated particulates, e.g. metal fume.

Class P3 intended for use against all particulates containing highly toxic materials, e.g. beryllium.

The local concentration of material, quantity and conditions of use determine the type of personal protective equipment required.

Use appropriate NIOSH-certified respirator based on informed professional judgement. In conditions where no reasonable estimate of exposure can be made, assume the exposure is in a concentration IDLH and use NIOSH-certified full face pressure demand SCBA with a minimum service life of 30 minutes, or a combination full facepiece pressure demand SAR with auxiliary self-contained air supply. Respirators provided only for escape from IDLH atmospheres shall be NIOSH-certified for escape from the atmosphere in which they will be used.

## ENGINEERING CONTROLS

■ Enclosed local exhaust ventilation is required at points of dust, fume or vapor generation.

HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapors.

Barrier protection or laminar flow cabinets should be considered for laboratory scale handling.

The need for respiratory protection should also be assessed where incidental or accidental exposure is anticipated: Dependent on levels of contamination, PAPR, full face air purifying devices with P2 or P3 filters or air supplied respirators should be evaluated.

Fume-hoods and other open-face containment devices are acceptable when face velocities of at least 1 m/s (200 feet/minute) are achieved. Partitions, barriers, and other partial containment technologies are required to prevent migration of the material to uncontrolled areas. For non-routine emergencies maximum local and general exhaust are necessary. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.

Type of Contaminant:	Air Speed:
solvent, vapors, etc. evaporating from tank (in still air)	0.25-0.5 m/s (50-100 f/min.)
aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers (released at low velocity into zone of active generation)	0.5-1 m/s (100-200 f/min.)
direct spray, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)	1-2.5 m/s (200-500 f/min.)

Within each range the appropriate value depends on:

Lower end of the range	Upper end of the range
1: Room air currents minimal or favourable to capture	1: Disturbing room air currents
2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity
3: Intermittent, low production.	3: High production, heavy use
4: Large hood or large air mass in motion	4: Small hood-local control only

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2.5 m/s (200-500 f/min.) for extraction of gases discharged 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.

## Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

### PHYSICAL PROPERTIES

Solid.

Does not mix with water.

State	Divided solid	Molecular Weight	405.55
Melting Range (°F)	Not available	Viscosity	Not Applicable
Boiling Range (°F)	Not available	Solubility in water (g/L)	Partly miscible
Flash Point (°F)	Not available	pH (1% solution)	Not available
Decomposition Temp (°F)	Not available	pH (as supplied)	Not applicable
Autoignition Temp (°F)	829.4	Vapour Pressure (mmHG)	Negligible
Upper Explosive Limit (%)	Not available.	Specific Gravity (water=1)	Not available
Lower Explosive Limit (%)	Not available	Relative Vapor Density (air=1)	>1

Volatile Component (%vol)	Negligible	Evaporation Rate	Not applicable
---------------------------	------------	------------------	----------------

## APPEARANCE

White to off-white to slightly yellow crystalline powder; mixes with water. Thermal stability: Slight exotherm with slow rate of release observed in closed bomb test, initiating around 60 deg. C. (for dihydrate)

## Section 10 - CHEMICAL STABILITY

### CONDITIONS CONTRIBUTING TO INSTABILITY

- 
- Presence of incompatible materials.
- Product is considered stable.
- Hazardous polymerization will not occur.

### STORAGE INCOMPATIBILITY

- Avoid reaction with oxidizing agents.

For incompatible materials - refer to Section 7 - Handling and Storage.

## Section 11 - TOXICOLOGICAL INFORMATION

lisinopril

### TOXICITY AND IRRITATION

- unless otherwise specified data extracted from RTECS - Register of Toxic Effects of Chemical Substances.

TOXICITY	IRRITATION
Oral (man) LDLo: 43 mg/kg/43w - I	Eye (rabbit): slight *
Oral (woman) LDLo: 1.2 mg/kg/16d - I	Skin (rabbit): slight *
Oral (rat) LD50: >8500 mg/kg	
Oral (rat) LD50: >20000 mg/kg *	
Subcutaneous (rat) LD50: >8500 mg/kg	
Intravenous (rat) LD50: >5200 mg/kg	
Oral (mouse) LD50: >20000 mg/kg *	
Subcutaneous (mouse) LD50: >9100 mg/kg	
Intravenous (mouse) LD50: >5500 mg/kg	
Oral (dog) LD50: >6000 mg/kg	

Changes in structures/ function of endocrine pancreas, decreased urine volume, somnolence, EKG changes (non-diagnostic), aplastic anaemia, changes in structure/ function salivary glands, dermatitis after systemic exposure, dyspnea, nausea, vomiting, interstitial nephritis, changes in serum composition, changes in potassium, changes in kidney tubules recorded.

#### for dihydrate:

Effects on newborn recorded.

\* Merck, Sharpe and Dohme

## Section 12 - ECOLOGICAL INFORMATION

Refer to data for ingredients, which follows:

LISINOPRIL:

- DO NOT discharge into sewer or waterways.

Daphnia magna LC50 >20000 mg/l

### Ecotoxicity

Ingredient	Persistence: Water/Soil	Persistence: Air	Bioaccumulation	Mobility
lisinopril	HIGH		LOW	LOW

## Section 13 - DISPOSAL CONSIDERATIONS

### Disposal Instructions

All waste must be handled in accordance with local, state and federal regulations.

† Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked.

A Hierarchy of Controls seems to be common - the user should investigate:

- Reduction
- Reuse
- Recycling
- Disposal (if all else fails)

This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate.



DO NOT allow wash water from cleaning equipment to enter drains. Collect all wash water for treatment before disposal.

- Recycle wherever possible.
- Consult manufacturer for recycling options or consult Waste Management Authority for disposal if no suitable treatment or disposal facility can be identified.
- Dispose of by: Burial in a licensed land-fill or Incineration in a licensed apparatus (after admixture with suitable combustible material)
- Decontaminate empty containers. Observe all label safeguards until containers are cleaned and destroyed.

## Section 14 - TRANSPORTATION INFORMATION

NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS: DOT, IATA, IMDG

## Section 15 - REGULATORY INFORMATION

**lisinopril (CAS: 83915-83-7,76547-98-3) is found on the following regulatory lists;**

"US - California Proposition 65 - Reproductive Toxicity", "US - Maine Chemicals of High Concern List"

## Section 16 - OTHER INFORMATION

### LIMITED EVIDENCE

- Ingestion may produce health damage\*.
- Cumulative effects may result following exposure\*.
- May possibly be harmful to the fetus/ embryo\*.

\* (limited evidence).

### Ingredients with multiple CAS Nos

Ingredient Name	CAS
lisinopril	83915-83-7, 76547-98-3

*Reasonable care has been taken in the preparation of this information, but the author makes no warranty of merchantability or any other warranty, expressed or implied, with respect to this information. The author makes no representations and assumes no liability for any direct, incidental or consequential damages resulting from its use. For additional technical information please call our toxicology department on +800 CHEMCALL.*

■ Classification of the mixture and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

A list of reference resources used to assist the committee may be found at:  
[www.chemwatch.net/references](http://www.chemwatch.net/references).

■ The (M)SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

*This document is copyright. Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.*

Issue Date: Oct-1-2008

Print Date: Apr-21-2010